TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37217137

Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Pars Plana Vitrectomy with Scleral Buckle (PPV-SB)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) with external subretinal fluid drainage
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) without external subretinal fluid drainage
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) and Pars Plana Vitrectomy with Scleral Buckle (PPV-SB)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Retinal displacement
Number of subjects: 91
Study: 37217183

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) therapy
Number of subjects: 25
Study: 37217188

Group type: EXPERIMENTAL
Intervention: High intensity care (HIC) strategy
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1077
Study: 37217243

Group type: EXPERIMENTAL
Intervention: IDO/PD-L1 targeting peptide vaccine combined with nivolumab (NCT03047928)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (patients in cohort B receiving anti-PD-1 therapy with peptide vaccine)
Number of subjects: 30
Study: 37217263

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in France
Number of subjects: 20012

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Germany
Number of subjects: 20012

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Italy
Number of subjects: 20012

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Japan
Number of subjects: 20012

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in US Explorys database
Number of subjects: 20012

Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in US TriNetX database
Number of subjects: 20012
Study: 37217262

Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (CS-EMR)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (HS-EMR)
Number of subjects: 232
Study: 37217267

Group type: EXPERIMENTAL
Intervention: COVID-PRESTO rapid serological test
Number of subjects: 3228
Study: 37217271

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection screening through PCR diagnosis
Number of subjects: 1000
Study: 37217273

Group type: EXPERIMENTAL
Intervention: TAS5315 4 or 2 mg once daily for 12 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: TAS5315
Number of subjects: 91
Study: 37217272

Group type: EXPERIMENTAL
Intervention: AKI-RRT
Number of subjects: 0
Study: 37217322

Group type: COMPARATOR
Intervention: Standard-of-care for weight management
Number of subjects: 57
Study: 37217318

Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate (VLC) diet
Number of subjects: 94

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 94
Study: 37217328

Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) digital intervention, 3 text messages per week asking for 3GT that occurred that day
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) digital intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 223
Study: 37217440

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 3956
Study: 37217511

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (Health Education)
Number of subjects: 93
Study: 37217882

Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (titration group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (5 cmH2O driving pressure)
Number of subjects: 53
Study: 37217885

Group type: EXPERIMENTAL
Intervention: FTD/TPI plus irinotecan
Number of subjects: 28
Study: 37217903

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Number of subjects: 402

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 402
Study: 37217911

Group type: EXPERIMENTAL
Intervention: Implant insertion with internal connection implants (Twinfit, Dentaurum, Ispringen, Germany) after piezoelectric implant site preparation.
Number of subjects: 90
Study: 37217960

Group type: EXPERIMENTAL
Intervention: One-on-one motivational interviewing (MI) sessions in addition to standard in-person audiological care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard in-person audiological care
Number of subjects: 0
Study: 37217980

Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 5
Study: 37218020

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) for 8 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 23
Study: 37218433

Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 0
Study: 37218591

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP)
Number of subjects: 201
Study: 37218631

Group type: EXPERIMENTAL
Intervention: TPVB-based opioid-free anaesthesia (OFA group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (control group)
Number of subjects: 80
Study: 37218688

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation in autistic females
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Emotion dysregulation in autistic males
Number of subjects: 74

Group type: COMPARATOR
Intervention: Emotion dysregulation in females with borderline personality disorder
Number of subjects: 74
Study: 37218946

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy guided by pre-RT Cho/NAA twice normal volume (Cho/NAA ≥ 2x)
Number of subjects: 0
Study: 37219010

Group type: EXPERIMENTAL
Intervention: Kidney Preservation Strategies
Number of subjects: 0
Study: 37219032

Group type: EXPERIMENTAL
Intervention: High AA/High Al-Anon involvement
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Low AA/Low Al-Anon involvement
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: High AA/Low Al-Anon involvement
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: High AA classes' COs
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: COs' Al-Anon involvement
Number of subjects: 279
Study: 37219072

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37219548

Group type: EXPERIMENTAL
Intervention: Telephone-based navigation intervention
Number of subjects: 225
Study: 37219607

Group type: EXPERIMENTAL
Intervention: Acute symptoms
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 425
Study: 37219686

Group type: EXPERIMENTAL
Intervention: Tovorafenib administered once every other day (Q2D) at RP2D of 200 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tovorafenib administered once weekly (QW) at RP2D of 600 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Tovorafenib (both Q2D and QW)
Number of subjects: 149
Study: 37219859

Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (BRAFi) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual inhibition of BRAF and ERK1/2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of ERK1/2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depletion of fibronectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous fibronectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined BRAF/ERK1/2 inhibition
Number of subjects: 0
Study: 37219865

Group type: EXPERIMENTAL
Intervention: Clenbuterol (40 μg daily increased to 80 μg twice daily)
Number of subjects: 25
Study: 37219901

Group type: EXPERIMENTAL
Intervention: AB-CASI (automated bilingual computerized alcohol screening and intervention)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: AB-CASI (for participants older than 25 years)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard care (for participants older than 25 years)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: AB-CASI (for participants 25 years or younger)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard care (for participants 25 years or younger)
Number of subjects: 840
Study: 37219930

Group type: COMPARATOR
Intervention: Stable isotope tracer methodology applied to liver slices and in vivo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 5
Study: 37219970

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 24 hours
Number of subjects: 146

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C for 24 hours
Number of subjects: 146
Study: 37220008

Group type: EXPERIMENTAL
Intervention: Total Antioxidant Capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 0
Study: 37220015

Group type: EXPERIMENTAL
Intervention: Patient-centered care with annual population HIV testing and universal ART
Number of subjects: 893

Group type: COMPARATOR
Intervention: Standard treatment model (baseline population testing with ART by country standard)
Number of subjects: 893
Study: 37220093

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 37220094

Group type: EXPERIMENTAL
Intervention: Intervention (cost-effective implementation)
Number of subjects: 0
Study: 37220119

Group type: EXPERIMENTAL
Intervention: Fortetropin® supplement (FOR-SUPP, n = 12) consuming 19.8 g/d of FOR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA-SUPP, n = 12) consuming energy- and macronutrient-matched cheese powder
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (FOR-SUPP and PLA-SUPP) after 2-wk of single-leg immobilization
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (FOR-SUPP and PLA-SUPP) after 2-wk of normal activity
Number of subjects: 24
Study: 37220130

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) of the incompetent saphenous trunk without tributary treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) concomitantly with truncal ablation
Number of subjects: 0
Study: 37220172

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11005
Study: 37220228

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 60
Study: 37220236

Group type: EXPERIMENTAL
Intervention: C-LIFE intervention (4-month program of dietary counseling, behavioral weight management, and exercise)
Number of subjects: 140

Group type: COMPARATOR
Intervention: SEPA (single counseling session providing standardized education and physician advice)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: C-LIFE intervention
Number of subjects: 140
Study: 37220393

Group type: EXPERIMENTAL
Intervention: Pecs block with ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 50
Study: 37220480

Group type: EXPERIMENTAL
Intervention: Casirivimab & imdevimab
Number of subjects: 265

Group type: COMPARATOR
Intervention: Remdesivir
Number of subjects: 265

Group type: COMPARATOR
Intervention: Favipravir
Number of subjects: 265
Study: 37220640

Group type: EXPERIMENTAL
Intervention: Ioxaglate (low-osmolarity iodine contrast)
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Iodixanol (iso-osmolarity iodine contrast)
Number of subjects: 2268
Study: 37220815

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Post-treatment CST close to estimated inflection points (217 to 256 μm)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 64
Study: 37220821

Group type: EXPERIMENTAL
Intervention: Targeted positioning of the LV lead towards the latest local electrical activation in the coronary sinus (CS)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Conventional LV lead positioning preferably in a nonapical posterolateral branch of the coronary sinus (CS)
Number of subjects: 1000
Study: 37220822

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study medications delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study visits adaptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 related endpoint adjudication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol and analytical plan revisions
Number of subjects: 0
Study: 37220893

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone
Number of subjects: 3211

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with bevacizumab
Number of subjects: 3211
Study: 37220958

Group type: EXPERIMENTAL
Intervention: microMend wound closure device
Number of subjects: 31
Study: 37220998

Group type: EXPERIMENTAL
Intervention: Tirofiban combined with Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with Aspirin
Number of subjects: 0
Study: 37221023

Group type: EXPERIMENTAL
Intervention: Value-based healthcare (VBHC) framework implementation
Number of subjects: 350
Study: 37221022

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: RSB
Number of subjects: 110

Group type: COMPARATOR
Intervention: TEA
Number of subjects: 110
Study: 37221027

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 25447

Group type: EXPERIMENTAL
Intervention: Overweight/Obese
Number of subjects: 25447

Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 25447

Group type: EXPERIMENTAL
Intervention: Socioeconomic status and empowerment
Number of subjects: 25447

Group type: EXPERIMENTAL
Intervention: Wealth quintile and food security
Number of subjects: 25447

Group type: EXPERIMENTAL
Intervention: Education level and food security
Number of subjects: 25447
Study: 37221030

Group type: EXPERIMENTAL
Intervention: Ages and Stages Questionnaire (ASQ)
Number of subjects: 1034
Study: 37221052

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: sNfL at attack
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: sGFAP, sTau, sUCHL1
Number of subjects: 1260
Study: 37221146

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 219
Study: 37221177

Group type: EXPERIMENTAL
Intervention: Low bolus + low infusion (15 mg + 0.6 mg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High bolus + high infusion (25 mg + 1 mg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low infusion (0.6 mg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High infusion (1 mg/min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 37221181

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 123
Study: 37221247

Group type: EXPERIMENTAL
Intervention: ProTrans (allogeneic Wharton's jelly-derived mesenchymal stromal cells)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 37221407

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: In-hospital pharmacotherapy optimization
Number of subjects: 1601
Study: 37221430

Group type: COMPARATOR
Intervention: Circulating levels of follistatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Circulating levels of FSTL3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Circulating levels of activin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Circulating levels of activin AB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activin AB/follistatin ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activin AB/FSTL3 ratio
Number of subjects: 0
Study: 37221447

Group type: EXPERIMENTAL
Intervention: Cognitive training combined with social engagement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Social engagement group without training
Number of subjects: 66
Study: 37221466

Group type: EXPERIMENTAL
Intervention: Live attenuated DENV3 monovalent vaccine rDEN3Δ30/31-7164
Number of subjects: 0
Study: 37221613

Group type: EXPERIMENTAL
Intervention: Periodic reinterpretation of CNVs of uncertain significance
Number of subjects: 259
Study: 37221704

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 61
Study: 37222099

Group type: EXPERIMENTAL
Intervention: Digital psychological self-care
Number of subjects: 36
Study: 37222151

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 37222189

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mFOLFIRINOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion of all cycles of planned adjuvant chemotherapy
Number of subjects: 0
Study: 37222204

Group type: EXPERIMENTAL
Intervention: Nivolumab as adjuvant treatment after curative surgery for oesophagal or gastroesophageal junction cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy in dMMR colorectal cancers
Number of subjects: 0
Study: 37222252

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40-60 mg/d)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combination ISMN-cilostazol (40-60 mg/d and 200 mg/d, respectively)
Number of subjects: 363

Group type: COMPARATOR
Intervention: No study drug (control group)
Number of subjects: 363
Study: 37222260

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with elevated alanine aminotransferase levels
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with elevated aspartate aminotransferase levels
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with hepatomegaly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with dyslipidaemia
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with liver biopsies
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with fibrosis-stage data
Number of subjects: 228
Study: 37222267

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37222316

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resupine position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 25
Study: 37222324

Group type: EXPERIMENTAL
Intervention: General anesthesia for cesarean section
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Early gestational weeks
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Neonates <3rd weight percentile
Number of subjects: 906
Study: 37222328

Group type: EXPERIMENTAL
Intervention: Maternal salivary cortisol level ≤24.20
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Maternal cortisol levels
Number of subjects: 400
Study: 37222468

Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy (2.5°C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (room temperature distilled water)
Number of subjects: 44
Study: 37222476

Group type: EXPERIMENTAL
Intervention: Early anticoagulation (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Later anticoagulation (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke)
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Early anticoagulation
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Later anticoagulation
Number of subjects: 2013
Study: 37222628

Group type: EXPERIMENTAL
Intervention: Endothelial function testing using EndoPAT 2000
Number of subjects: 300
Study: 37222663

Group type: EXPERIMENTAL
Intervention: Direct R0 without further resection
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Converted R0 after positive intraoperative pathology consultation (IOC) and extension of resection
Number of subjects: 679

Group type: COMPARATOR
Intervention: R1 status
Number of subjects: 679

Group type: COMPARATOR
Intervention: Converted R0
Number of subjects: 679
Study: 37222671

Group type: EXPERIMENTAL
Intervention: Pre-COVID
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Peri-COVID
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Pan University Hospital rotations
Number of subjects: 271
Study: 37222685

Group type: EXPERIMENTAL
Intervention: Resected lymph nodes (24 or more) in patients with positive lymph nodes (N+)
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Resected lymph nodes (15-23) in patients with positive lymph nodes (N+)
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Resected lymph nodes (N0 group)
Number of subjects: 1624
Study: 37222717

Group type: EXPERIMENTAL
Intervention: Reverse Shock Index multiplied by the Glasgow Coma Scale (rSIG)
Number of subjects: 105641

Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 105641

Group type: COMPARATOR
Intervention: Modified Shock Index (MSI)
Number of subjects: 105641
Study: 37222716

Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles-derived lncRNA-GC1
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles-derived lncRNA-GC1 response
Number of subjects: 798
Study: 37222787

Group type: EXPERIMENTAL
Intervention: Controlled breakfast containing H
Number of subjects: 6